A Study of Lorigerlimab in Participants With Advanced Solid Tumors

This study is testing a new immunotherapy drug called lorigerlimab in women with two specific types of advanced, hard-to-treat gynecological cancers: platinum-resistant ovarian cancer (PROC) and clear cell gynecological cancers (CCGC) affecting the ovaries, endometrium, vagina, vulva, or cervix. **You may be eligible if...** - You have been confirmed by biopsy to have high-grade serous ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum chemotherapy, OR - You have confirmed clear cell cancer of the ovary, endometrium, vagina, vulva, or cervix - Your cancer has progressed or come back after prior treatment - You have received 1 to 3 prior lines of therapy (for ovarian cancer) or at least 1 prior line (for clear cell cancer) - If you have a BRCA gene mutation, you have previously received a PARP inhibitor - You have at least one measurable tumor on scans - You are willing to provide a tumor biopsy or have archived tissue available **You may NOT be eligible if...** - You have primary platinum-refractory disease (cancer that never responded to first-line platinum therapy) - You have previously received checkpoint inhibitor immunotherapy (anti-PD-1, anti-PD-L1, anti-CTLA-4) for ovarian cancer — though prior use for clear cell endometrial or cervical cancers may be allowed - You have active brain metastases - You have had an organ or stem cell transplant - You are pregnant, planning to be pregnant, or breastfeeding - You have another active cancer diagnosed within the past 3 years Talk to your doctor to see if this trial is right for you.